You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of novel therapeutics for cancer cachexia

    SBC: EMMYON, INC.            Topic: NCI

    PROJECT SUMMARY / ABSTRACT Cancer-induced skeletal muscle atrophy is a central and defining feature of the cancer cachexia syndrome, a highly prevalent condition that affects over 50% of patients with advanced cancer and over 500,000 patients per year in the U.S. In addition to being highly prevalent, cancer-induced skeletal muscle atrophy has devastating consequences for patients; it reduces phys ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a Modular Flexible Semi-Disposable Endoscope Platform

    SBC: ELEMENTS ENDOSCOPY, INC            Topic: NIBIB

    Project Summary/AbstractEndoscopy is an important tool in the diagnosis and treatment of many gastrointestinal, urological, and kidney diseases. Endoscopes have typically been reusable and are cleaned with high level disinfection (HLD) between patients. Publications and reports in recent years have shown that endoscopes are not sufficiently cleaned between patients, resulting in unacceptable level ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Point-of-care lateral flow immunoassay for diagnosis of pertussis

    SBC: DXDISCOVERY INC            Topic: NIAID

    Pertussis (Whooping cough) is a highly contagious, airborne disease that is rapidly re-emerging as a serious public health threat in the United States. Despite high vaccine coverage, annual reported cases in the U.S. have been increasing recently, with an average of 25,000 per year from 2010-2019. This is a level unseen since the early 1960s. Diagnosis of pertussis is challenging because its early ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Tissue Oxygen Scanning for Acute Compartment Syndrome (ACS) Diagnosis

    SBC: ASCAN LLC            Topic: NIAMS

    PROJECT SUMMARY Acute compartment syndrome (ACS) is a complication of extremity injury caused by increasingly elevated intracompartmental pressure (ICP) that eventually compromises perfusion, causing ischemia of the muscles within the compartment. If this persists longer than 6-8 hours, permanent ischemic damage to the muscle occurs (myofibrosis and ischemic contracture). ACS demands immediate sur ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: 100

    Abstract Duchenne Muscular Dystrophy (DMD) is a fatal muscle disease with an incidence of 1 in 5000 males. DMD results from mutations in the gene encoding dystrophin, a 427 kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and laminin in the extracellular matrix. The α7β1 integrin is a transmembrane linkage system in skeletal and card ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Treating non-small cell lung tumors with a novel inhaled dry powder chemotherapeutic formulation

    SBC: Quench Medical Inc.            Topic: 102

    Project Summary / Abstract Significance Lung cancer is the leading cause of cancer mortality with a 5-year survival rate of less than 20% following standard of care therapy. Problem Despite the use of aggressive surgery, combination chemotherapy and immunotherapy, a major limitation in the control of primary and metastatic non-small cell pulmonary tumors with the use of the systemic administration ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. In vivo feasibility of a smart needle ablation treatment for liver cancer

    SBC: CURRENT SURGICAL INC            Topic: 102

    Project Summary A significant number (~30-50%) of liver cancers have no curative treatments due to their proximity to critical anatomy. Minimally invasive thermal ablation is a promising treatment for these untreatable solid tumors. If delivered precisely, ablations offer the treatment efficacy of traditional surgery with lower patient risk, clinician time, and overall cost. Existing ablation tech ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Closed-loop attention bias modification brain training for opioid use disorder

    SBC: NEUROTYPE INC.            Topic: NIDA

    Project Summary / Abstract Significance: In 2021, more than 75,000 people in the United States died from opioid overdoses. Clinics that treat Opioid Use Disorder (OUD) lack Food and Drug Administration (FDA)-regulated devices that can be prescribed to alleviate cravings and prevent drug use and overdoses. The objective of this SBIR Phase I project is to develop and test a portable neurotherapeutic ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Allogeneic BAFF Ligand Based CAR T Cells as a Novel Therapy for B Cell Malignancies

    SBC: LUMINARY THERAPEUTICS, INC.            Topic: 102

    ABSTRACT Since the first FDA approval of chimeric antigen receptor (CAR) T cell therapy in 2017, the use of engineered T cells expressing specific CARs to treat cancer has generated durable cures for many patients. Nevertheless, a significant subset of patients with B cell malignancies relapse following treatment due to lack of CAR T cell persistence and the ability of cancer cells to change with ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Previvors Recharge: A Resilience Program for Cancer Previvors

    SBC: Pro-Change Behavior Systems, Inc.            Topic: 102

    It is estimated that approximately 5-10% of all diagnosed cancers are caused by Hereditary Cancer Syndromes (HCS) that are associated with germline mutations (inherited genetic mutations passed directly from a parent to a child that create a genetic predisposition to certain types of cancer). Recent epidemiologic models indicate that 1 in 279 people may be carriers of one of the most common HCS, a ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government